Fulgent To Present Clinical Data For Its Lead Therapeutic Oncology Candidate, FID-007, At ASCO 2024 Annual Meeting

5/24/24 8:03:14 AM ET

Medical Specialities

Health Care

Get the next $FLGT alert in real time by email

Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ:FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois.

Get the next $FLGT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FLGT

Date	Price Target	Rating	Analyst
12/7/2023	$35.00	Neutral	UBS
12/8/2022	$65.00 → $40.00	Overweight → Neutral	Piper Sandler
11/18/2022	$45.00	Outperform	Raymond James
8/25/2022	$65.00	Outperform	Credit Suisse
2/4/2022	$80.00	Overweight	Piper Sandler
1/25/2022	$141.00 → $125.00	Outperform	Oppenheimer
8/10/2021	$55.00 → $65.00	Underperform	Credit Suisse
8/5/2021	$55.00	Underperform	Credit Suisse

More analyst ratings

Fulgent Reports Third Quarter 2024 Financial Results
Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million, or $0.31 per share A
11/8/24 7:00:00 AM ET
$FLGT
Medical Specialities
Health Care
Fulgent to Participate in Upcoming Conferences
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 11:30 AM Eastern Time Live webcasts of the sessions will be available on the Investor Relations section of the Fulgent website at ir.fulgentgenetics.com. Replay of the webcasts will be accessible at the same location be
11/5/24 8:00:00 AM ET
$FLGT
Medical Specialities
Health Care
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans. A leader in clinical molecular diagnostic testing, Fulgent has been periodically providing genetic testing services to the members of the VA since 2017. These have included both clinical and research-based services. This new award enables Fulgent to provide hereditary cancer tests to individuals with cancer or a family
10/31/24 8:00:00 AM ET
$FLGT
Medical Specialities
Health Care

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
6/10/24 1:00:00 AM ET
$FLGT
$NEO
Medical Specialities
Health Care
Precision Instruments
Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain
After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
5/14/24 9:00:00 AM ET
$FLGT
Medical Specialities
Health Care
Exagen Inc. Appoints Paul Kim to Board of Directors
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public
7/24/23 4:05:00 PM ET
$FLGT
$XGN
Medical Specialities
Health Care

Fulgent Reports Third Quarter 2024 Financial Results
Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million, or $0.31 per share A
11/8/24 7:00:00 AM ET
$FLGT
Medical Specialities
Health Care
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is
10/17/24 4:05:00 PM ET
$FLGT
Medical Specialities
Health Care
Fulgent Reports Second Quarter 2024 Financial Results
Total Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Results: Total Revenue of $71.0 million Core Revenue1 grew 5% year-over-year to $70.2 million GAAP loss of $8.7 million, or ($0.29) per share Non-GAAP income of $4.7 million, or $0.15 per share
8/2/24 7:00:00 AM ET
$FLGT
Medical Specialities
Health Care

Fulgent To Present Clinical Data For Its Lead Therapeutic Oncology Candidate, FID-007, At ASCO 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for $FLGT

$FLGT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

$FLGT SEC Filings

SEC Form 10-Q filed by Fulgent Genetics Inc.

Fulgent Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by Fulgent Genetics Inc.

$FLGT Press Releases

Fastest customizable press release news feed in the world

$FLGT Leadership Updates

Live Leadership Updates

$FLGT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$FLGT Market Insights

Live Market Insights

Fulgent Reports Third Quarter 2024 Financial Results

Fulgent to Participate in Upcoming Conferences

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

Exagen Inc. Appoints Paul Kim to Board of Directors

Chief Executive Officer Hsieh Ming covered exercise/tax liability with 1,337 shares, decreasing direct ownership by 0.19% to 705,938 units (SEC Form 4)

Chief Scientific Officer Gao Hanlin covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.01% to 921,339 units (SEC Form 4)

CFO and Treasurer Kim Paul covered exercise/tax liability with 2,738 shares, decreasing direct ownership by 1% to 206,743 units (SEC Form 4)